Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals (SUPN) will participate in two September 2026 investor conferences, featuring management fireside chats in New York and Boston-area venues.
The company is scheduled for the Cantor Global Healthcare Conference on September 9, 2026 at 2:45 p.m. ET at the Waldorf Astoria in New York, and the Wells Fargo Healthcare Conference on September 10, 2026 at 12:45 p.m. ET at Encore Boston Harbor in Everett, Massachusetts. Investors are directed to contact conference coordinators to arrange meetings. A live audio webcast of the Jefferies Global Healthcare Conference and 60‑day archived replays will be accessible via the Events & Presentations section of the company’s website.
Supernus Pharmaceuticals (NASDAQ: SUPN) announced a partnership with professional snowboarder Chloe Kim, who will serve as a compensated ambassador to share her journey with ADHD and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant ADHD medication for patients 6 years and older.
The collaboration aims to raise awareness of adult ADHD, encourage patient–doctor dialogue, and challenge misconceptions. According to Supernus, Qelbree has approximately 3 million prescriptions since its 2021 launch, offers 24-hour exposure, no evidence of abuse potential, flexible dosing, and is the #1 prescribed branded non-stimulant ADHD medication as of May 2026.
Supernus (Nasdaq: SUPN) reported second quarter 2026 total revenues of $219.1 million, up 32% year over year, with combined revenues from its four growth products rising 52% to $175.7 million. Qelbree net sales grew 15% to $89.2 million, GOCOVRI rose 2% to $37.6 million, ONAPGO reached $13.5 million, and collaboration revenue from ZURZUVAE was $35.4 million.
Total net product sales increased 5% to $165.7 million, and total revenues from commercial products (non-GAAP) were $201.1 million, up 27%. The company reported a second quarter operating loss of $58.0 million, driven mainly by a non-cash $54.9 million APOKYN intangible asset impairment, versus operating earnings of $12.1 million a year earlier. Adjusted operating earnings (non-GAAP) were $31.2 million, down from $40.9 million. Cash and investments rose to $372.1 million as of June 30, 2026. Supernus raised its full year 2026 total revenue guidance to $860–$890 million and adjusted operating earnings guidance to $150–$180 million, and disclosed a definitive all-stock merger-of-equals agreement with Indivior Pharmaceuticals to form a larger CNS-focused biopharmaceutical company.
Supernus Pharmaceuticals (Nasdaq: SUPN) and Indivior Pharmaceuticals (Nasdaq: INDV) agreed to a tax-free, all-stock merger of equals to form a diversified CNS biopharmaceutical company with pro forma net revenue of approximately $2.2 billion and pro forma adjusted EBITDA of $888 million, including $125 million in expected annual cost synergies.
Supernus stockholders will receive 1.5401 Indivior shares per share and Indivior stockholders will receive a one-time special cash dividend of $1.0 billion, funded by a committed $650 million term loan from Citibank N.A. and existing cash. Indivior holders will own about 56.5% of the combined company and Supernus holders about 43.5%. The merged entity will be named Supernus, Inc., listed on Nasdaq as SUPN, headquartered in Rockville, Maryland, led by Supernus CEO Jack Khattar as President and CEO and Indivior director Tony Kingsley as Board Chair. Closing is targeted for Q4 2026, subject to shareholder and regulatory approvals.
Supernus Pharmaceuticals (Nasdaq: SUPN) will report its second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. Management will host a conference call and live webcast at 4:30 p.m. ET, with Q&A, webcast access via the Investor Relations site, and a replay available for 60 days.
Supernus (Nasdaq: SUPN) marks the five-year anniversary of FDA approval for Qelbree (viloxazine extended-release), a once-daily, non-stimulant ADHD treatment for patients aged 6 years and older. Initially approved for children and adolescents in April 2021 and expanded to adults in April 2022, Qelbree has become a widely used option, with approximately 3 million prescriptions filled since launch and over 1 million in 2025.
According to Supernus, Qelbree is the first novel non-stimulant ADHD medicine in over a decade and the first and only ADHD treatment with serotonin (5-HT2C) pharmacodynamics in its FDA labeling. A January 2025 label update added multimodal pharmacodynamic data and lactation data, supporting its use with 24-hour exposure, flexible dosing, and no evidence of abuse potential. The company also reiterates Qelbree’s Boxed Warning about increased risk of suicidal thoughts and actions, cardiovascular monitoring, potential for mania, sedation, drug interaction cautions, and common side effects in pediatric and adult patients.
Supernus Pharmaceuticals (Nasdaq: SUPN) will participate in two June 2026 investor conferences focused on healthcare.
Management joins the Jefferies Global Healthcare Conference on June 3, 2026, including a webcasted fireside chat, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that Jack A. Khattar, President and CEO, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026 at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas.
Investors may request meetings through the Bank of America coordinator. A live audio webcast and a 60-day archived replay will be available via the company’s Investor Relations Events & Presentations page at www.supernus.com/Investors.
Supernus (Nasdaq: SUPN) reported Q1 2026 total revenues of $207.7M, up 39% year-over-year, driven by combined growth-product revenues of $149.1M (+56%). Qelbree sales were $77.9M (+20%) and GOCOVRI $35.2M (+15%). Collaboration revenue from ZURZUVAE was $27.6M. Operating loss narrowed to $8.3M; adjusted operating earnings were $28.7M. Net loss was $2.3M (EPS $0.04). Cash and equivalents were ~$384.2M. Company reiterated full-year 2026 guidance, including total revenue target of $840–$870M and ONAPGO sales guidance of $45–$70M.
Supernus Pharmaceuticals (Nasdaq: SUPN) will report its first quarter 2026 financial and business results after market close on Tuesday, May 5, 2026. Management will host a conference call and webcast the same day at 4:30 p.m. ET with prepared remarks followed by Q&A.
The live webcast will be available in the Events & Presentations section of the company investor website and replayed for 60 days. Participants may pre-register to receive dial-in details and a personalized conference code; dial-in is recommended 15 minutes early.